Tissue | Expression Dynamics | Abbreviation |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ILK_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ILK_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ILK_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ILK_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ILK_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ILK_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00016573 | Endometrium | AEH | ureteric bud development | 20/2100 | 91/18723 | 2.31e-03 | 1.74e-02 | 20 |
GO:00720804 | Endometrium | AEH | nephron tubule development | 20/2100 | 91/18723 | 2.31e-03 | 1.74e-02 | 20 |
GO:00518965 | Endometrium | AEH | regulation of protein kinase B signaling | 34/2100 | 185/18723 | 2.55e-03 | 1.88e-02 | 34 |
GO:00721633 | Endometrium | AEH | mesonephric epithelium development | 20/2100 | 92/18723 | 2.64e-03 | 1.93e-02 | 20 |
GO:00721643 | Endometrium | AEH | mesonephric tubule development | 20/2100 | 92/18723 | 2.64e-03 | 1.93e-02 | 20 |
GO:00332098 | Endometrium | AEH | tumor necrosis factor-mediated signaling pathway | 21/2100 | 99/18723 | 2.87e-03 | 2.05e-02 | 21 |
GO:00459278 | Endometrium | AEH | positive regulation of growth | 44/2100 | 259/18723 | 3.28e-03 | 2.30e-02 | 44 |
GO:0048662 | Endometrium | AEH | negative regulation of smooth muscle cell proliferation | 17/2100 | 75/18723 | 3.39e-03 | 2.36e-02 | 17 |
GO:00456692 | Endometrium | AEH | positive regulation of osteoblast differentiation | 16/2100 | 69/18723 | 3.46e-03 | 2.39e-02 | 16 |
GO:00434914 | Endometrium | AEH | protein kinase B signaling | 37/2100 | 211/18723 | 3.89e-03 | 2.64e-02 | 37 |
GO:00305166 | Endometrium | AEH | regulation of axon extension | 20/2100 | 95/18723 | 3.91e-03 | 2.64e-02 | 20 |
GO:00720282 | Endometrium | AEH | nephron morphogenesis | 17/2100 | 76/18723 | 3.92e-03 | 2.64e-02 | 17 |
GO:00149103 | Endometrium | AEH | regulation of smooth muscle cell migration | 19/2100 | 89/18723 | 4.12e-03 | 2.73e-02 | 19 |
GO:00900922 | Endometrium | AEH | regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 43/2100 | 256/18723 | 4.47e-03 | 2.93e-02 | 43 |
GO:00149092 | Endometrium | AEH | smooth muscle cell migration | 20/2100 | 97/18723 | 5.00e-03 | 3.14e-02 | 20 |
GO:0014912 | Endometrium | AEH | negative regulation of smooth muscle cell migration | 11/2100 | 42/18723 | 5.45e-03 | 3.37e-02 | 11 |
GO:003367310 | Endometrium | AEH | negative regulation of kinase activity | 40/2100 | 237/18723 | 5.47e-03 | 3.38e-02 | 40 |
GO:190121416 | Endometrium | AEH | regulation of neuron death | 51/2100 | 319/18723 | 5.82e-03 | 3.55e-02 | 51 |
GO:00507725 | Endometrium | AEH | positive regulation of axonogenesis | 17/2100 | 79/18723 | 5.93e-03 | 3.59e-02 | 17 |
GO:00720882 | Endometrium | AEH | nephron epithelium morphogenesis | 16/2100 | 73/18723 | 6.21e-03 | 3.70e-02 | 16 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ILK | SNV | Missense_Mutation | | c.903N>A | p.Met301Ile | p.M301I | Q13418 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
ILK | SNV | Missense_Mutation | | c.1096G>A | p.Glu366Lys | p.E366K | Q13418 | protein_coding | tolerated(0.14) | benign(0.066) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-BH-A0BR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ILK | SNV | Missense_Mutation | rs752302392 | c.62N>G | p.Asp21Gly | p.D21G | Q13418 | protein_coding | deleterious(0.01) | probably_damaging(0.958) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ILK | SNV | Missense_Mutation | | c.539N>C | p.Gly180Ala | p.G180A | Q13418 | protein_coding | tolerated(1) | benign(0.003) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ILK | SNV | Missense_Mutation | novel | c.205N>C | p.Thr69Pro | p.T69P | Q13418 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
ILK | SNV | Missense_Mutation | novel | c.606T>G | p.Asn202Lys | p.N202K | Q13418 | protein_coding | tolerated(0.11) | benign(0.212) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
ILK | SNV | Missense_Mutation | rs752932911 | c.239N>A | p.Arg80His | p.R80H | Q13418 | protein_coding | tolerated(0.49) | benign(0.017) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | | US8754233, (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine | | |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | | US8754233, 4-(5-Fluoro-6-methoxy-benzothiazol-2-yl)-5-(2-fluoro-phenyl)-2H-pyrazol-3-ylamine | | |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | inhibitor | 249565796 | | |
3611 | ILK | SERINE THREONINE KINASE, DRUGGABLE GENOME, KINASE, ENZYME | | US8754233, 2-(3-Amino-1H-pyrazol-4-yl)-5-fluoro-benzothiazole-6-sulfonic acid amide | | |